Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Mivavotinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mivavotinib | TAK-659|TAK659 | SYK Inhibitor 14 | Mivavotinib (TAK-659) is an inhibitor of spleen tyrosine kinase (SYK), which may lead to B-cell inhibition and antitumor activity (PMID: 32327472). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | chronic lymphocytic leukemia | not applicable | Mivavotinib | Case Reports/Case Series | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 60% (3/5, 3 partial responses) in patients with relapsed or refractory chronic lymphocytic leukemia, with a median duration of response not reached (PMID: 32327472; NCT02000934). | 32327472 |
Unknown unknown | lymphoma | not applicable | Mivavotinib | Phase I | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 40% (27/67, 12 complete responses, 15 partial responses) in patients with relapsed or refractory diffuse large B-cell lymphoma, with a median duration of response of 856 days (PMID: 32327472; NCT02000934). | 32327472 |
Unknown unknown | follicular lymphoma | not applicable | Mivavotinib | Case Reports/Case Series | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 89% (8/9, 2 complete responses, 6 partial responses) in patients with relapsed or refractory follicular lymphoma, with a median duration of response of 137 days (PMID: 32327472; NCT02000934). | 32327472 |
Unknown unknown | diffuse large B-cell lymphoma | not applicable | Mivavotinib | Phase I | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 28% (12/43, 8 complete responses, 4 partial responses) in patients with relapsed or refractory diffuse large B-cell lymphoma, with a median duration of response not reached (PMID: 32327472; NCT02000934). | 32327472 |
Unknown unknown | mantle cell lymphoma | not applicable | Mivavotinib | Case Reports/Case Series | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 33% (1/3, 1 partial responses) in patients with relapsed or refractory mantle cell lymphoma, with a median duration of response of 109 days (PMID: 32327472; NCT02000934). | 32327472 |
Unknown unknown | non-Hodgkin lymphoma | not applicable | Mivavotinib | Case Reports/Case Series | Actionable | In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 73% (11/15, 4 complete responses, 7 partial responses) in patients with relapsed or refractory indolent non-Hodgkin lymphoma, with a median duration of response of 176 days (PMID: 32327472; NCT02000934). | 32327472 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03359733 | Phase I | Mivavotinib | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | Withdrawn | USA | 0 |
NCT03123393 | Phase II | Mivavotinib | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | CAN | 4 |
NCT02551055 | Phase I | Docetaxel Paclitaxel Alisertib Mivavotinib MLN1117 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | Terminated | USA | 1 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Active, not recruiting | USA | 3 |
NCT02323113 | Phase Ib/II | Mivavotinib | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | Completed | USA | CAN | 0 |